EZZ taps University of Sydney for bone growth supplement research

• EZZ inks research services deal with University of Sydney for study on effects of a supplement on bone growth
• Two-year project will assess an EZZ proprietary formulation and is expected to conclude in March 2027
• Project reflects EZZ’s commitment to advance life science through research with academic institutions

Special Report: Life science company EZZ Life Science has joined forces with the University of Sydney in a cutting-edge research project to investigate the effects of a novel multi-ingredient supplement on bone growth.

The research services agreement marks a key step in the strategy of EZZ Life Science Holdings (ASX: EZZ) to develop scientifically backed health products, with the study set to explore how a unique blend of nutrients could support stronger, healthier bones.

Under the collaboration – to be led by Associate Professor Zufu Lu and Professor Hala Zreiqat of the School of Biomedical Engineering – in vitro research will examine effects of a novel multi-ingredient nutritional supplement on bone growth.

The two-year project will assess a proprietary formulation containing lysine, calcium carbonate, vitamin D3, vitamin B2, zinc gluconate, taurine, glutamine, glycine and magnesium.

The research will evaluate the formulation’s potential to support bone health using advanced cellular and molecular models.

Scientifically validated health and wellness products

The project with the University of Sydney reflects EZZ’s broader commitment to advance life science through credible, high-impact research with academic institutions.

Through these collaborations and focused research areas, EZZ continues to expand its range of health and wellness products, aiming to provide scientifically validated solutions to consumers globally.

Under the agreement, the university will provide annual progress reports and a final report upon completion of the research, which is expected to conclude by March 2027.

‘Important step in our strategy’

EZZ’s Non-Executive Chair Glenn Cross said the company was excited to work with the University of Sydney on the important research initiative.

“Their world-class biomedical research capabilities and rigorous scientific standards make them an ideal institution to help evaluate and validate our formulation,” he said.

“This study represents an important step in our strategy to invest in evidence-based innovation and drive the development of products that support long-term health outcomes.”

This article was developed in collaboration with EZZ Life Science Holdings, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.